In this episode, Marta Wosinska discusses the complexities of pharmaceutical quality oversight, focusing on the roles of the FDA and the differences in regulations between the US and EU. She highlights the importance of good manufacturing practices, the challenges faced by manufacturers, and the implications of cost-cutting on drug quality. The conversation also touches on the future of drug manufacturing regulations and the potential for increased oversight in response to supply chain issues.
In this episode, Tomas Philipson, a professor at the University of Chicago and former acting chair of the Council of Economic Advisors, alongside financial analyst Thom Gunderson and pharmaceutical expert Briana Mayer, discusses drug innovation, pricing policies, and the role of the FDA in the drug approval processes. Philipson shares insights on the impact of U.S. pharmaceutical spending on global health, critiques the Most Favored Nation pricing model, and emphasizes the importance of innovation in healthcare. The conversation also touches on the implications of the Inflation Reduction Act on drug development and the feedback from the pharmaceutical sector regarding recent policy changes.
In this episode, Tony Losasso, a professor of economics and Driehaus Fellow at Depaul University, discusses his experiences in public service, particularly his role in the Center for Program Integrity at CMS during the implementation of the Affordable Care Act. He shares insights on the challenges of government work, the importance of translating academic research into public understanding, and the role of pharmaceuticals in addressing obesity from his recent Wall Street Journal op-ed.
In EP4, Bryana Meyer joins us to talk with Doug Holtz-Eakin, former CBO head and president of the American Action Forum.
On this episode, Marta Wosinska of the Brookings Institution talks about drug shortages and the challenges of preventing them.
In EP2, we interview Karen Mandelbaum at Epstein Becker Green and discuss her work at CMS drafting privacy standards for the public health exchanges after the passage of the Affordable Care Act.
In the first episode of On Background, we talk to Paul Howard, former senior advisor to the commissioner of the FDA, about the developing role of AI in healthcare.